Shares of Biogen Inc. BIIB shed 3.41% to $150.03 Friday, on what proved to be an all-around mixed trading session for the ...
Integrated Wealth Concepts LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 61.3% during the third ...
Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has ...
It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined ...
As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...
Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
GET MORE AI-GENERATED SIGNALS: November 30, 2024, 22:30 pm ET, BY Rick O.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
Biogen Inc. closed $112.97 below its 52-week high ($268.30), which the company achieved on January 3rd.
BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback